» Articles » PMID: 36552942

The Role of Noninvasive C-Octanoate Breath Test in Assessing the Diagnosis of Nonalcoholic Steatohepatitis

Overview
Specialty Radiology
Date 2022 Dec 23
PMID 36552942
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The diagnosis of NASH needs a liver biopsy, an invasive procedure that is not frequently accepted by patients. The aim of our study was to evaluate the efficacy of the C-Octanoate breath test (OBT) as a non-invasive surrogate marker to differentiate patients with NASH from patients with simple steatosis (NAFL).

Methods: We performed a prospective study on patients with histologically established non-alcoholic steatohepatitis and no other hepatic disease. Each patient underwent a testing protocol, which included a clinical exam, laboratory blood tests, standard abdominal ultrasound, and a C-Octanoate breath test.

Results: The study group included: 82 patients with steatohepatitis, 64 patients with simple steatosis, and 21 healthy volunteers. The univariate and bivariate analysis identified that significant values were the percent dose recovery (PDR) at 15 min-r = 0.65 (AUROC = 0.902) and cumulative percent dose recovery (cPDR) at 120 min-r = 0.69 (AUROC = 0.899).

Discussion: Our study showed that C-OBT had good efficacy for identifying patients with NASH from those with NAFL (steatosis alone) but not those with NAFL from healthy subjects. Considering all these pathogenic steps in NASH we considered that OBT could have the clinical utility to identify patients at risk for NASH, especially "fast progressors".

Citing Articles

Gut microbiota in MAFLD: therapeutic and diagnostic implications.

Alghamdi W, Mosli M, Alqahtani S Ther Adv Endocrinol Metab. 2024; 15:20420188241242937.

PMID: 38628492 PMC: 11020731. DOI: 10.1177/20420188241242937.


A Comparison of C-Methacetin and C-Octanoate Breath Test for the Evaluation of Nonalcoholic Steatohepatitis.

Fierbinteanu-Braticevici C, Enciu V, Calin-Necula A, Papacocea I, Moldoveanu A J Clin Med. 2023; 12(6).

PMID: 36983160 PMC: 10051674. DOI: 10.3390/jcm12062158.

References
1.
Dornas W, Schuppan D . Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020; 319(3):G400-G411. DOI: 10.1152/ajpgi.00121.2020. View

2.
Lauterburg B . Assessment of liver function prior to hepatic resection. Swiss Surg. 1999; 5(3):92-6. DOI: 10.1024/1023-9332.5.3.92. View

3.
Younossi Z, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H . Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6):524-530.e1. DOI: 10.1016/j.cgh.2011.03.020. View

4.
Singh S, Khera R, Allen A, Murad M, Loomba R . Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015; 62(5):1417-32. DOI: 10.1002/hep.27999. View

5.
DeLany J, Windhauser M, Champagne C, Bray G . Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr. 2000; 72(4):905-11. DOI: 10.1093/ajcn/72.4.905. View